Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)
Annette F. Okai
Lilyana Amezcua
Regina R. Berkovich
Angel R. Chinea
Keith R. Edwards
Brian Steingo
Aljoeson Walker
Alan K. Jacobs
Nadia Daizadeh
Mitzi J. Williams
on behalf of CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators
10.6084/m9.figshare.9918761.v1
https://adisjournals.figshare.com/articles/figure/Efficacy_and_Safety_of_Alemtuzumab_in_Patients_of_African_Descent_with_Relapsing-Remitting_Multiple_Sclerosis_8-Year_Follow-up_of_CARE-MS_I_and_II_TOPAZ_Study_/9918761
<p><strong>Provide enhanced digital features for this article</strong><br></p><p>
If you are an author of this publication and would like to provide additional
enhanced digital features for your article then please contact <u>adisrapidplus@springer.com</u>.<br>
<br>
The journal offers a range of additional features designed to increase
visibility and readership. All features will be thoroughly peer reviewed to
ensure the content is of the highest scientific standard and all features are
marked as ‘peer reviewed’ to ensure readers are aware that the content has been
reviewed to the same level as the articles they are being presented alongside.
Moreover, all sponsorship and disclosure information is included to provide
complete transparency and adherence to good publication practices. This ensures
that however the content is reached the reader has a full understanding of its
origin. No fees are charged for hosting additional open access content.<br>
<br>
Other enhanced features include, but are not limited to:<br>
• Slide decks<br>
• Videos and animations<br>
• Audio abstracts<br>
• Audio slides</p>
2019-10-18 08:43:32
African descent
Alemtuzumab
Disease-modifying therapy
Multiple sclerosis